New medicines are no longer one-size-fits-all. Therapies are more complex, manufactured in smaller batches and personalized for specific patient groups or even individuals. New pharmaceutical manufacturing technologies with greater flexibility, cost-effectiveness and quality assurance are needed to make those therapies. Seated at their laptops, a microbiologist and an engineer wrote a business plan to upend how injectable therapies are manufactured.…
Read More

Imaging Technique May Reduce Cost, Timeline of Clinical Trials in MS

“Think of a multiple sclerosis lesion as the tip of the iceberg,” says Dr. Alex Rauscher. “It’s not just what’s happening inside the lesion that we need to think about – what happens in the surrounding tissue affects the brain as well.” By using advanced, highly-sensitive magnetic resonance imaging (MRI) techniques, Dr. Rauscher and his team are hoping to better…
Read More
In one of the most comprehensive studies to date, UBC researchers have identified potential adverse reactions of a commonly used multiple sclerosis drug. The study aimed to identify potential adverse events related to beta-interferon treatment for relapsing-remitting multiple sclerosis by analyzing health records of over 2,000 British Columbians with multiple sclerosis between 1995 and 2008. “Once a drug is released…
Read More
Researchers investigating genetically predisposed or at-risk individuals and their families affected by early onset cardiovascular disease (CVD), have received an additional $400K in funding from Genome BC and the Providence Health Care Research Institute (PCHRI) to continue this important work. The study, called SAVE BC (Study to Avoid cardioVascular Events in British Columbia) is aimed at identifying and closely observing…
Read More

New MSFHR Awards For 11 Health Professional Researchers

MSFHR has announced 11 award recipients for its inaugural Health Professional-Investigator Program. These exceptional health professionals will receive funding to support research focused on answering questions derived from their practical experience and clinical expertise. The MSFHR Health Professional-Investigator Program is designed to develop BC’s research talent and help decrease the gap between health research and its implementation. The awards support…
Read More
Vancouver virtual life sciences company Novelogics Biotechnology Inc. has partnered with the Centre for Drug Research and Development (CDRD) to work on an innovative cancer treatment. Novelogics, which focuses on using the immune system to eliminate tumours in ways that have fewer side effects than traditional methods, has developed a technology that involves the discovery and development of antibodies that…
Read More
Faculty of Medicine scientists have uncovered seven new subtypes of ovarian cancer, which could result in new treatment strategies for some ovarian cancer patients including those that do not respond well to chemotherapy. The discovery, published in Nature Genetics, analyzed the genetic information of more than 100 ovarian cancer patients in order to identify abnormalities in the DNA of ovarian cancer…
Read More
Cancer-causing gene mutations were found in the pelvic lesions of women with a typically non-cancerous gynecological disorder called endometriosis, a study by Vancouver scientists published Wednesday by the New England Journal of Medicine shows. Endometriosis causes intense pelvic pain, menstrual abnormalities and even infertility. It is characterized by tissue that normally lines the uterus migrating outside the organ, causing lesions throughout the pelvic cavity. The bumpy…
Read More
(Left to right) Dr. Fabio Rossi, William Kennedy, Roza Vaez Ghaemi, Dr. Katharina Rhothe, Stephanie Campbell, Sanam Shafaatablab, and Dr. Allen Eaves at the BC Regenerative Medicine Symposium. On May 10th, scientists and trainees in the field of stem cell biology attended the first ever BC Regenerative Medicine Symposium at the UBC Pharmaceutical Sciences building. The full day event featured…
Read More
Zymeworks Inc. today announced the closing of its initial public offering of 4,500,000 common shares at an initial offering price of U.S.$13.00 per share, for a total of U.S.$58,500,000 in aggregate gross proceeds. Zymeworks expects to use the net proceeds from the offering to further develop and advance its pipeline of product candidates and to increase its liquidity. In addition,…
Read More